Skip to main content
SpringerLink
Log in

Therapeutic Modalities in Early-Stage Uterine Papillary Serous Carcinomas, Carcinosarcomas, Clear-Cell and Mixed Histology Carcinomas

Building a Case for Combined Chemotherapy and Radiation

  • Chapter
  • First Online:
Uterine Cancer

Part of the book series: Current Clinical Oncology ((CCO))

Abstract

The entities covered in this chapter are uterine papillary serous carcinoma (UPSC), carcinosarcoma, and clear-cell carcinoma together with tumors of mixed histology. Overall, these represent 3–5% of all endometrial cancers but they are responsible for a significant percentage of endometrial cancer mortality. Recent strides in chemotherapy of some of these cancers offer hope that their addition, either alone or as part of combined modality treatment including radiation, will lead to improvements in survival.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer Statistics, 2008. CA Cancer J Clin 2008;58(2):271–296.

    Article  Google Scholar 

  2. Rosenberg P, Blom R, Hogberg T, Simonsen E. Death rate and recurrence pattern among 841 clinical stage I endometrial cancer patients with special reference to uterine papillary serous carcinoma. Gynecol Oncol, 1993;51: 311–315.

    Article  PubMed  CAS  Google Scholar 

  3. Lauchlan SC. Tubal (serous) carcinoma of the endometrium. Arch Pathol Lab Med, 1981;105: 615–618.

    PubMed  CAS  Google Scholar 

  4. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol, 1982;6: 93–108.

    Article  PubMed  CAS  Google Scholar 

  5. Kato DT, Ferry JA, Goodman A, et al Uterine papillary serous carcinoma (UPSC): a clinicopathologic study of 30 cases. Gynecol Oncol, 1995;59: 384–389.

    Article  PubMed  CAS  Google Scholar 

  6. Turner BC, Knisely JP, Kacinski BM, et al Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy. Int J Radiat Oncol Biol Phys, 1998;40: 77–84.

    Article  PubMed  CAS  Google Scholar 

  7. Cirisano FD, Jr, Robboy SJ, Dodge RK, et al The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol, 2000;77: 55–65.

    Article  PubMed  Google Scholar 

  8. Platz CE, Benda JA. Female genital tract cancer. Cancer, 1995;75: 270–294.

    Article  PubMed  CAS  Google Scholar 

  9. Grice J, Ek M, Greer B, et al Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients. Gynecol Oncol, 1998;69: 69–73.

    Article  PubMed  CAS  Google Scholar 

  10. Goff BA, Kato D, Schmidt RA, et al Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol, 1994;54: 264–268.

    Article  PubMed  CAS  Google Scholar 

  11. Tay EH, Ward BG. The treatment of uterine papillary serous carcinoma (UPSC): are we doing the right thing? Int J Gynecol Cancer, 1999;9: 463–469.

    Article  PubMed  Google Scholar 

  12. Bristow RE, Asrari F, Trimble EL, Montz FJ. Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I-III) disease. Gynecol Oncol, 2001;81: 279–286.

    Article  PubMed  CAS  Google Scholar 

  13. Abramovich D, Markman M, Kennedy A, Webster K, Belinson J. Serum CA-125 as a marker of disease activity in uterine papillary serous carcinoma. J Cancer Res Clin Oncol, 1999;125: 697–698.

    Article  PubMed  CAS  Google Scholar 

  14. Boruta DM, 2nd, Gehrig PA, Groben PA, et al Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference? Cancer, 2004;101: 2214–2221.

    Article  PubMed  Google Scholar 

  15. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch, 2004;444: 213–223.

    Article  PubMed  CAS  Google Scholar 

  16. Slomovitz BM, Burke TW, Eifel PJ, et al Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol, 2003;91: 463–469.

    Article  PubMed  Google Scholar 

  17. Chan JK, Loizzi V, Youssef M, et al Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium. Gynecol Oncol, 2003;90: 181–185.

    Article  PubMed  Google Scholar 

  18. Geisler JP, Geisler HE, Melton ME, Wiemann MC. What staging surgery should be performed on patients with uterine papillary serous carcinoma? Gynecol Oncol, 1999;74: 465–467.

    Article  PubMed  CAS  Google Scholar 

  19. Carcangiu ML, Chambers JT. Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma. Gynecol Oncol, 1992;47: 298–305.

    Article  PubMed  CAS  Google Scholar 

  20. Kelly MG, O’Malley DM, Hui P, et al Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol, 2005;98: 353–359.

    Article  PubMed  CAS  Google Scholar 

  21. Lim P, Al Kushi A, Gilks B, Wong F, Aquino-Parsons C. Early stage uterine papillary serous carcinoma of the endometrium: effect of adjuvant whole abdominal radiotherapy and pathologic parameters on outcome. Cancer, 2001;91: 752–757.

    Article  PubMed  CAS  Google Scholar 

  22. Sood BM, Jones J, Gupta S, et al Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma. Int J Radiat Oncol Biol Phys, 2003;57: 208–216.

    Article  PubMed  Google Scholar 

  23. Mehta N, Yamada SD, Rotmensch J, Mundt AJ. Outcome and pattern of failure in pathologic stage I-II papillary serous carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys, 2003;57: 1004–1009.

    Article  PubMed  Google Scholar 

  24. Keys HM, Roberts JA, Brunetto VL, et al A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol, 2004;92: 744–751.

    Article  PubMed  Google Scholar 

  25. Huh WK, Powell M, Leath CA, 3rd, et al Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. Gynecol Oncol, 2003;91: 470–475.

    Article  PubMed  Google Scholar 

  26. Hamilton CA, Liou WS, Osann K, et al Impact of adjuvant therapy on survival of patients with early-stage uterine papillary serous carcinoma. Int J Radiat Oncol Biol Phys, 2005;63: 839–844.

    Article  PubMed  Google Scholar 

  27. Elit L, Kwon J, Bentley J, Trim K, Ackerman I, Carey M. Optimal management for surgically Stage 1 serous cancer of the uterus. Gynecol Oncol, 2004;92: 240–246.

    Article  PubMed  CAS  Google Scholar 

  28. Dietrich CS, Modesitt SC, DePriest PD, et al The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC). Gynecol Oncol, 2005;99: 557–563.

    Article  PubMed  CAS  Google Scholar 

  29. Ramondetta L, Burke TW, Levenback C, Bevers M, Bdurka-Bevers D, Gershenson DM. Treatment of uterine papillary serous carcinoma with paclitaxel. Gynecol Oncol, 2001;82: 156–161.

    Article  PubMed  CAS  Google Scholar 

  30. Bancher-Todesca D, Neunteufel W, Williams KE, et al Influence of postoperative treatment on survival in patients with uterine papillary serous carcinoma. Gynecol Oncol, 1998;71: 344–347.

    Article  PubMed  CAS  Google Scholar 

  31. Low JS, Wong EH, Tan HS, et al Adjuvant sequential chemotherapy and radiotherapy in uterine papillary serous carcinoma. Gynecol Oncol, 2005;97: 171–177.

    Article  PubMed  Google Scholar 

  32. Fakiris AJ, Moore DH, Reddy SR, et al Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: a phase II Hoosier Oncology Group (HOG 97-01) study. Gynecol Oncol, 2005;96: 818–823.

    Article  PubMed  CAS  Google Scholar 

  33. Bitterman P, Chun B, Kurman RJ. The significance of epithelial differentiation in mixed mesodermal tumors of the uterus. A clinicopathologic and immunohistochemical study. Am J Surg Pathol, 1990;14: 317–328.

    Article  PubMed  CAS  Google Scholar 

  34. Kounelis S, Jones MW, Papadaki H, Bakker A, Swalsky P, Finkelstein SD. Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components. Hum Pathol, 1998;29: 82–87.

    Article  PubMed  CAS  Google Scholar 

  35. Emoto M, Iwasaki H, Kikuchi M, Shirakawa K. Characteristics of cloned cells of mixed mullerian tumor of the human uterus. Carcinoma cells showing myogenic differentiation in vitro. Cancer, 1993;71: 3065–3075.

    Article  PubMed  CAS  Google Scholar 

  36. Wada H, Enomoto T, Fujita M, et al Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res, 1997;57: 5379–5385.

    PubMed  CAS  Google Scholar 

  37. Fujii H, Yoshida M, Gong ZX, et al Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. Cancer Res, 2000;60: 114–120.

    PubMed  CAS  Google Scholar 

  38. Silverberg SG, Major FJ, Blessing JA, et al Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol, 1990;9: 1–19.

    Article  PubMed  CAS  Google Scholar 

  39. Fleming WP, Peters WA, Kumar NB, Morley GW. Autopsy findings in patients with uterine sarcoma. Gynecol Oncol, 1984;19: 168–172.

    Article  PubMed  CAS  Google Scholar 

  40. Amant F, Cadron I, Fuso L, et al Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. Gynecol Oncol, 2005;98: 274–280.

    Article  PubMed  Google Scholar 

  41. Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989–1999. Gynecol Oncol, 2004;93: 204–208.

    Article  PubMed  Google Scholar 

  42. Inthasorn P, Carter J, Valmadre S, Beale P, Russell P, Dalrymple C. Analysis of clinicopathologic factors in malignant mixed Mullerian tumors of the uterine corpus. Int J Gynecol Cancer, 2002;12: 348–353.

    Article  PubMed  CAS  Google Scholar 

  43. McCluggage WG, Abdulkader M, Price JH, et al Uterine carcinosarcomas in patients receiving tamoxifen. A report of 19 cases. Int J Gynecol Cancer, 2000;10: 280–284.

    Article  PubMed  Google Scholar 

  44. Major FJ, Blessing JA, Silverberg SG, et al Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer, 1993;71: 1702–1709.

    Article  PubMed  CAS  Google Scholar 

  45. Nielsen SN, Podratz KC, Scheithauer BW, O’Brien PC. Clinicopathologic analysis of uterine malignant mixed mullerian tumors. Gynecol Oncol, 1989;34: 372–378.

    Article  PubMed  CAS  Google Scholar 

  46. Ramondetta LM, Burke TW, Jhingran A, et al A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed mullerian tumors with evaluation of potential molecular targets. Gynecol Oncol, 2003;90: 529–536.

    Article  PubMed  CAS  Google Scholar 

  47. Yamada SD, Burger RA, Brewster WR, Anton D, Kohler MF, Monk BJ. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer, 2000;88: 2782–2786.

    Article  PubMed  CAS  Google Scholar 

  48. Wolfson AH, Brady MF, Rocereto T, et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I–IV carcinosarcoma of the uterus. Gynecol Oncol 2007; 107(2): 177–85.

    Google Scholar 

  49. Gerszten K, Faul C, Kounelis S, Huang Q, Kelley J, Jones MW. The impact of adjuvant radiotherapy on carcinosarcoma of the uterus. Gynecol Oncol, 1998;68: 8–13.

    Article  PubMed  CAS  Google Scholar 

  50. Molpus KL, Redlin-Frazier S, Reed G, Burnett LS, Jones HW. Postoperative pelvic irradiation in early stage uterine mixed mullerian tumors. Eur J Gynaecol Oncol, 19: 541–546, 1998.

    PubMed  CAS  Google Scholar 

  51. Knocke TH, Weitmann HD, Kucera H, Kolbl H, Pokrajac B, Potter R. Results of primary and adjuvant radiotherapy in the treatment of mixed Mullerian tumors of the corpus uteri. Gynecol Oncol, 1999;73: 389–395.

    Article  PubMed  CAS  Google Scholar 

  52. Chi DS, Mychalczak B, Saigo PE, Rescigno J, Brown CL. The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma. Gynecol Oncol, 1997;65: 493–498.

    Article  PubMed  CAS  Google Scholar 

  53. Le T. Adjuvant pelvic radiotherapy for uterine carcinosarcoma in a high risk population. Eur J Surg Oncol, 27: 282–285, 2001.

    Article  PubMed  CAS  Google Scholar 

  54. Callister M, Ramondetta LM, Jhingran A, Burke TW, Eifel PJ. Malignant mixed Mullerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys, 2004;58: 786–796.

    Article  PubMed  Google Scholar 

  55. Sartori E, Bazzurini L, Gadducci A, et al Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study. Gynecol Oncol, 1997;67: 70–75.

    Article  PubMed  CAS  Google Scholar 

  56. Omura GA, Blessing JA, Major F, et al A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol, 1985;3: 1240–1245.

    PubMed  CAS  Google Scholar 

  57. Sutton GP, Blessing JA, Rosenshein N, Photopulos G, DiSaia PJ. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study). Am J Obstet Gynecol, 1989;161: 309–312.

    PubMed  CAS  Google Scholar 

  58. Sutton G, Brunetto VL, Kilgore L, et al A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol, 79: 147–153, 2000.

    Article  PubMed  CAS  Google Scholar 

  59. Sutton G, Kauderer J, Carson LF, et al Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol, 2005;96: 630–634.

    Article  PubMed  CAS  Google Scholar 

  60. Resnik E, Chambers SK, Carcangiu ML, Kohorn EI, Schwartz PE, Chambers JT. A phase II study of etoposide, cisplatin, and doxorubicin chemotherapy in mixed mullerian tumors (MMT) of the uterus. Gynecol Oncol, 1995;56: 370–375.

    Article  PubMed  CAS  Google Scholar 

  61. Curtin JP, Blessing JA, Soper JT, DeGeest K. Paclitaxel in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol, 2001;83: 268–270.

    Article  PubMed  CAS  Google Scholar 

  62. Miller DS, Blessing JA, Schilder J, Munkarah A, Lee YC. Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol, 2005;98: 217–221.

    Article  PubMed  CAS  Google Scholar 

  63. Homesley HD, Filiaci V, Markman M, et al Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group study. J Clin Oncol 2007;25(5):526–31.

    Article  PubMed  CAS  Google Scholar 

  64. Toyoshima M, Akahira J, Matsunaga G, et al Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus. Gynecol Oncol, 2004;94: 774–778.

    Article  PubMed  CAS  Google Scholar 

  65. Odunsi K, Moneke V, Tammela J, et al Efficacy of adjuvant CYVADIC chemotherapy in early-stage uterine sarcomas: results of long-term follow-up. Int J Gynecol Cancer, 2004;14: 659–664.

    Article  PubMed  CAS  Google Scholar 

  66. Kohorn EI, Schwartz PE, Chambers JT, Peschel RE, Kapp DS, Merino M. Adjuvant therapy in mixed mullerian tumors of the uterus. Gynecol Oncol, 1986;23: 212–221.

    Article  PubMed  CAS  Google Scholar 

  67. Manolitsas TP, Wain GV, Williams KE, Freidlander M, Hacker NF. Multimodality therapy for patients with clinical Stage I and II malignant mixed Mullerian tumors of the uterus. Cancer, 2001;91: 1437–1443.

    Article  PubMed  CAS  Google Scholar 

  68. Menczer J, Levy T, Piura B, et al A comparison between different postoperative treatment modalities of uterine carcinosarcoma. Gynecol Oncol, 2005;97: 166–170.

    Article  PubMed  Google Scholar 

  69. Scully RE, Barlow JF. “Mesonephroma” of ovary. Tumor of Mullerian nature related to the endometrioid carcinoma. Cancer, 1967;20: 1405–1417.

    Article  PubMed  CAS  Google Scholar 

  70. Kanbour-Shakir A, Tobon H. Primary clear cell carcinoma of the endometrium: a clinicopathologic study of 20 cases. Int J Gynecol Pathol, 1991;10: 67–78.

    Article  PubMed  CAS  Google Scholar 

  71. Craighead PS, Sait K, Stuart GC, et al Management of aggressive histologic variants of endometrial carcinoma at the Tom Baker Cancer Centre between 1984 and 1994. Gynecol Oncol, 2000;77: 248–253.

    Article  PubMed  CAS  Google Scholar 

  72. Cirisano FD Jr, Robboy SJ, Dodge RK, et al Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol, 1999;74: 385–394.

    Article  PubMed  Google Scholar 

  73. Abeler VM, Kjorstad KE. Clear cell carcinoma of the endometrium: a histopathological and clinical study of 97 cases. Gynecol Oncol, 1991;40: 207–217.

    Article  PubMed  CAS  Google Scholar 

  74. Carcangiu ML, Chambers JT. Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival. Int J Gynecol Pathol, 1995;14: 30–38.

    Article  PubMed  CAS  Google Scholar 

  75. Creasman WT, Kohler MF, Odicino F, Maisonneuve P, Boyle P. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol, 2004;95: 593–596.

    Article  PubMed  Google Scholar 

  76. McMeekin DS, Filiaci VL, Thigpen JT, Gallion HH, Fleming GF, Rodgers WH. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemo therapy trials: a Gynecologic Oncology Group study. Gynecol Oncol, 2007;106:16–22.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, MO

    Nicholas P. Taylor & Matthew A. Powell

Authors
  1. Nicholas P. Taylor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthew A. Powell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew A. Powell .

Editor information

Editors and Affiliations

    Rights and permissions

    Reprints and permissions

    Copyright information

    © 2009 Humana Press, a part of Springer Science+Business Media, LLC

    About this chapter

    Cite this chapter

    Taylor, N.P., Powell, M.A. (2009). Therapeutic Modalities in Early-Stage Uterine Papillary Serous Carcinomas, Carcinosarcomas, Clear-Cell and Mixed Histology Carcinomas. In: Oliva, E., Muggia, F. (eds) Uterine Cancer. Current Clinical Oncology. Humana Press. https://doi.org/10.1007/978-1-60327-044-1_10

    Download citation

    • DOI: https://doi.org/10.1007/978-1-60327-044-1_10

    • Published:

    • Publisher Name: Humana Press

    • Print ISBN: 978-1-58829-736-5

    • Online ISBN: 978-1-60327-044-1

    • eBook Packages: MedicineMedicine (R0)

    Publish with us

    Policies and ethics

    Search

    Navigation